UW neuroscientists led by Su-Chun Zhang found that neurons derived from stem cells can connect with native neurons and restore motor functions. But more research is needed to translate the findings from mice to people.
Researchers believe the same approach can be applied to several other respiratory pathogens, including the novel coronavirus that causes COVID-19.
Leaders and staff at UW–Madison, including people who care for and provide oversight of our animals, take seriously our responsibility to care for animals in research.
The trials center around an “antibody cocktail” called REGN-COV2, which was created by the New York-based pharmaceutical company Regeneron.
UW–Madison researchers have developed a safer and more efficient way to deliver a promising new method for treating cancer and liver disorders and for vaccination — including a COVID-19 vaccine that has advanced to clinical trials.
The animals are useful to researchers trying to understand SARS-CoV-2 and in the evaluation of vaccines, treatments and drugs against the disease it causes.
Researchers advise that people with symptoms avoid contact with cats, and cat owners should keep their pets indoors to limit contact with other people and animals.
Work by Brian Parks and collaborators provides a new target for understanding the genetic risk of high cholesterol, which is linked to heart disease.
Although the global surge in demand has made it more difficult in many places, WSLH’s colleagues at the university have pitched in to keep testing available in Wisconsin.
Refinement of the CoroFlu vaccine concept and testing in laboratory animal models at UW–Madison is expected to take three to six months. CoroFlu could be in human clinical trials by fall, 2020.